Effect of reconstruction settings and therapy on 18F-FDG PET/CT blood pool and liver SUV in patients with diffuse large B-cell lymphoma

Theo van den Belt, Coreline Burggraaff, Otto Hoekstra, Josée Zijlstra, Henrica de Vet, Ronald Boellaard

Research output: Contribution to journalMeeting AbstractAcademic

Abstract

608Objectives: The PET Re-Analysis (PETRA) project is an international consortium building a shared database consisting of individual patient data and 18F-FDG PET/CT scans. PETRA aims to re-analyze interim PET/CT scans in diffuse large B-cell lymphoma (DLBCL) to validate interim PET/CT as a biomarker of response in first-line therapy. The EANM guidelines for tumor imaging 2.0 suggest that liver and blood pool standardized uptake values (SUVs) may be used for quality control to verify e.g. correct FDG administration or technically correct scanner performance. Moreover, the ICML response criteria compare tumor uptake to liver and blood pool uptake. For validation of interim PET/CT as an imaging biomarker, the quality control of PET/CT scans is essential to assure harmonized quality of pooled PETRA data. To this end, we investigated whether reconstruction settings, therapy and use of growth factors influenced liver and blood pool SUVs in DLBCL patients.Methods: PET/CT scans of DLBCL patients were collected from the HOVON 84 study, a multicenter randomized controlled trial. Patients were treated with R-CHOP14 therapy and were randomized to receive rituximab intensification in the first four cycles or not. Granulocyte-colony stimulating factor (G-CSF) was given to oppose neutropenic side effects. Therapy was not adapted based on interim PET/CT results. Liver and mediastinal blood pool (MBP) uptakes were analyzed in 123 baseline PET/CT scans to determine the effect of reconstruction settings. Based on the EANM Research Ltd (EARL) criteria, we created 3 groups; EARL compliant, non-EARL compliant and unknown. Liver and MBP SUVs were analyzed at baseline, interim (after 4 cycles of chemotherapy) and end-of treatment for 34 DLBCL patients to determine the influence of therapy. Interim scan timing was defined as time between the start of the fourth R-CHOP14 cycle and interim PET/CT. Differences in SUV variance between reconstruction settings were analyzed using Levene’s test. Baseline, interim and end-of-treatment SUVs were compared using paired samples t-test (p <0.05 was considered to be significant). Correlation between SUV and interim scan timing was analyzed using linear regression.Results: No significant differences in variances between the various SUVs were seen in EARL compliant baseline scans compared to unknown or non-EARL compliant scans. As is shown in Figure 1, a significant increase was seen in liver SUVmean (+0.414 p =
Original languageEnglish
Pages (from-to)608
Number of pages1
JournalJournal of Nuclear Medicine
Volume58
Issue numbersupplement 1
Publication statusPublished - 2017

Cite this

@article{c6e52097bb3b4c069a831b0ac8fbd044,
title = "Effect of reconstruction settings and therapy on 18F-FDG PET/CT blood pool and liver SUV in patients with diffuse large B-cell lymphoma",
abstract = "608Objectives: The PET Re-Analysis (PETRA) project is an international consortium building a shared database consisting of individual patient data and 18F-FDG PET/CT scans. PETRA aims to re-analyze interim PET/CT scans in diffuse large B-cell lymphoma (DLBCL) to validate interim PET/CT as a biomarker of response in first-line therapy. The EANM guidelines for tumor imaging 2.0 suggest that liver and blood pool standardized uptake values (SUVs) may be used for quality control to verify e.g. correct FDG administration or technically correct scanner performance. Moreover, the ICML response criteria compare tumor uptake to liver and blood pool uptake. For validation of interim PET/CT as an imaging biomarker, the quality control of PET/CT scans is essential to assure harmonized quality of pooled PETRA data. To this end, we investigated whether reconstruction settings, therapy and use of growth factors influenced liver and blood pool SUVs in DLBCL patients.Methods: PET/CT scans of DLBCL patients were collected from the HOVON 84 study, a multicenter randomized controlled trial. Patients were treated with R-CHOP14 therapy and were randomized to receive rituximab intensification in the first four cycles or not. Granulocyte-colony stimulating factor (G-CSF) was given to oppose neutropenic side effects. Therapy was not adapted based on interim PET/CT results. Liver and mediastinal blood pool (MBP) uptakes were analyzed in 123 baseline PET/CT scans to determine the effect of reconstruction settings. Based on the EANM Research Ltd (EARL) criteria, we created 3 groups; EARL compliant, non-EARL compliant and unknown. Liver and MBP SUVs were analyzed at baseline, interim (after 4 cycles of chemotherapy) and end-of treatment for 34 DLBCL patients to determine the influence of therapy. Interim scan timing was defined as time between the start of the fourth R-CHOP14 cycle and interim PET/CT. Differences in SUV variance between reconstruction settings were analyzed using Levene’s test. Baseline, interim and end-of-treatment SUVs were compared using paired samples t-test (p <0.05 was considered to be significant). Correlation between SUV and interim scan timing was analyzed using linear regression.Results: No significant differences in variances between the various SUVs were seen in EARL compliant baseline scans compared to unknown or non-EARL compliant scans. As is shown in Figure 1, a significant increase was seen in liver SUVmean (+0.414 p =",
author = "{van den Belt}, Theo and Coreline Burggraaff and Otto Hoekstra and Jos{\~A}{\circledC}e Zijlstra and {de Vet}, Henrica and Ronald Boellaard",
year = "2017",
language = "English",
volume = "58",
pages = "608",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "supplement 1",

}

Effect of reconstruction settings and therapy on 18F-FDG PET/CT blood pool and liver SUV in patients with diffuse large B-cell lymphoma. / van den Belt, Theo; Burggraaff, Coreline; Hoekstra, Otto; Zijlstra, Josée; de Vet, Henrica; Boellaard, Ronald.

In: Journal of Nuclear Medicine, Vol. 58 , No. supplement 1 , 2017, p. 608.

Research output: Contribution to journalMeeting AbstractAcademic

TY - JOUR

T1 - Effect of reconstruction settings and therapy on 18F-FDG PET/CT blood pool and liver SUV in patients with diffuse large B-cell lymphoma

AU - van den Belt, Theo

AU - Burggraaff, Coreline

AU - Hoekstra, Otto

AU - Zijlstra, Josée

AU - de Vet, Henrica

AU - Boellaard, Ronald

PY - 2017

Y1 - 2017

N2 - 608Objectives: The PET Re-Analysis (PETRA) project is an international consortium building a shared database consisting of individual patient data and 18F-FDG PET/CT scans. PETRA aims to re-analyze interim PET/CT scans in diffuse large B-cell lymphoma (DLBCL) to validate interim PET/CT as a biomarker of response in first-line therapy. The EANM guidelines for tumor imaging 2.0 suggest that liver and blood pool standardized uptake values (SUVs) may be used for quality control to verify e.g. correct FDG administration or technically correct scanner performance. Moreover, the ICML response criteria compare tumor uptake to liver and blood pool uptake. For validation of interim PET/CT as an imaging biomarker, the quality control of PET/CT scans is essential to assure harmonized quality of pooled PETRA data. To this end, we investigated whether reconstruction settings, therapy and use of growth factors influenced liver and blood pool SUVs in DLBCL patients.Methods: PET/CT scans of DLBCL patients were collected from the HOVON 84 study, a multicenter randomized controlled trial. Patients were treated with R-CHOP14 therapy and were randomized to receive rituximab intensification in the first four cycles or not. Granulocyte-colony stimulating factor (G-CSF) was given to oppose neutropenic side effects. Therapy was not adapted based on interim PET/CT results. Liver and mediastinal blood pool (MBP) uptakes were analyzed in 123 baseline PET/CT scans to determine the effect of reconstruction settings. Based on the EANM Research Ltd (EARL) criteria, we created 3 groups; EARL compliant, non-EARL compliant and unknown. Liver and MBP SUVs were analyzed at baseline, interim (after 4 cycles of chemotherapy) and end-of treatment for 34 DLBCL patients to determine the influence of therapy. Interim scan timing was defined as time between the start of the fourth R-CHOP14 cycle and interim PET/CT. Differences in SUV variance between reconstruction settings were analyzed using Levene’s test. Baseline, interim and end-of-treatment SUVs were compared using paired samples t-test (p <0.05 was considered to be significant). Correlation between SUV and interim scan timing was analyzed using linear regression.Results: No significant differences in variances between the various SUVs were seen in EARL compliant baseline scans compared to unknown or non-EARL compliant scans. As is shown in Figure 1, a significant increase was seen in liver SUVmean (+0.414 p =

AB - 608Objectives: The PET Re-Analysis (PETRA) project is an international consortium building a shared database consisting of individual patient data and 18F-FDG PET/CT scans. PETRA aims to re-analyze interim PET/CT scans in diffuse large B-cell lymphoma (DLBCL) to validate interim PET/CT as a biomarker of response in first-line therapy. The EANM guidelines for tumor imaging 2.0 suggest that liver and blood pool standardized uptake values (SUVs) may be used for quality control to verify e.g. correct FDG administration or technically correct scanner performance. Moreover, the ICML response criteria compare tumor uptake to liver and blood pool uptake. For validation of interim PET/CT as an imaging biomarker, the quality control of PET/CT scans is essential to assure harmonized quality of pooled PETRA data. To this end, we investigated whether reconstruction settings, therapy and use of growth factors influenced liver and blood pool SUVs in DLBCL patients.Methods: PET/CT scans of DLBCL patients were collected from the HOVON 84 study, a multicenter randomized controlled trial. Patients were treated with R-CHOP14 therapy and were randomized to receive rituximab intensification in the first four cycles or not. Granulocyte-colony stimulating factor (G-CSF) was given to oppose neutropenic side effects. Therapy was not adapted based on interim PET/CT results. Liver and mediastinal blood pool (MBP) uptakes were analyzed in 123 baseline PET/CT scans to determine the effect of reconstruction settings. Based on the EANM Research Ltd (EARL) criteria, we created 3 groups; EARL compliant, non-EARL compliant and unknown. Liver and MBP SUVs were analyzed at baseline, interim (after 4 cycles of chemotherapy) and end-of treatment for 34 DLBCL patients to determine the influence of therapy. Interim scan timing was defined as time between the start of the fourth R-CHOP14 cycle and interim PET/CT. Differences in SUV variance between reconstruction settings were analyzed using Levene’s test. Baseline, interim and end-of-treatment SUVs were compared using paired samples t-test (p <0.05 was considered to be significant). Correlation between SUV and interim scan timing was analyzed using linear regression.Results: No significant differences in variances between the various SUVs were seen in EARL compliant baseline scans compared to unknown or non-EARL compliant scans. As is shown in Figure 1, a significant increase was seen in liver SUVmean (+0.414 p =

M3 - Meeting Abstract

VL - 58

SP - 608

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - supplement 1

ER -